It was anticipated that data from this clinical trial will be available in the first half of 2014.
In this randomised, double-blind, placebo-controlled crossover study, a total of 20 adults with idiopathic pulmonary fibrosis (IPF) will be treated, by inhalation, with a single nebulized dose of VRP700.
Patients with IPF typically cough many times per hour and the efficacy of the drug in these patients will be assessed by measuring the change in frequency and severity of their cough.
Verona Pharma is a drug development company focused on "first-in-class" medicines to treat respiratory diseases.
Story provided by StockMarketWire.com